In two recent studies, WelChol, a drug already approved for lowering LDL (bad) cholesterol was found to lower A1c’s in patients with type 2 diabetes. The first study showed that WelChol, when added to insulin, lowered A1c’s by an average of 0.5% compared to a placebo group.
In the second study, WelChol added to an oral antidiabetic therapy again resulted in mean A1c reductions of 0.5% compared to the placebo group.
As a result of these findings, the manufacturer has applied for approval to market their drug as a one-two punch for both cholesterol and type 2 diabetes. If approved, it will be the first drug to target both conditions.
* * *
Source: WelChol Press Release